Clinical studies have confirmed that some of chemotherapeutic agents can mediate the antitumor immune response in patients by increasing the proportion and number of CD8+ TIL cells in the tumor microenvironment (13, 8, 14). The gene discussed is CD8A; the disease is neoplasm.